TXT
59
6
APH
65
4
BMY
43
2
NVDA
55
4
DFS
60
4
PDCO
41
3
ROP
53
2
V
56
2
YUM
43
5
DGX
36
3
MS
69
3
GILD
62
2
BRK.B
27
2
GIS
29
3
F
42
2
STZ
47
-3
ITW
64
2
PH
71
4
PPL
54
5
MHK
46
3
TXT
59
6
APH
65
4
BMY
43
2
NVDA
55
4
DFS
60
4
PDCO
41
3
ROP
53
2
V
56
2
YUM
43
5
DGX
36
3
MS
69
3
GILD
62
2
BRK.B
27
2
GIS
29
3
F
42
2
STZ
47
-3
ITW
64
2
PH
71
4
PPL
54
5
MHK
46
3
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!
Sell
44

PTGX
Protagonist Therapeutics

Last Price:
47.53
Seasonality Move:
18.58%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Protagonist Therapeutics Price Quote

$47.53
+1.63 (+3.55%)
(Updated: November 6, 2024 at 2:35 PM ET)

Protagonist Therapeutics Key Stats

Sell
44
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$43.86 - $47.31
52-week range:
$14.78 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.99%
Volume:
848.5K
Avg. volume:
500.7K
1-year change:
175.68%
Market cap:
$2.7B
Revenue:
$60M
EPS:
$2.62

How Much Does Protagonist Therapeutics Make?

Data Unavailable

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $231.5M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $45.6M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$156.9M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 41.77%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 37.73%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 41.77%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -21.11%
Revenue: 0% -37.5%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 53.38
Upside from Last Price: 16.29%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    105.5M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders